Latest News From Lumira Ventures

New Patient-Reported Outcomes Data Shows Trilaciclib Improves Chemotherapy Experience for Patients

Jennifer Schram G1 Therapeutics, Portfolio News, Press Release

G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today presented additional findings from a randomized Phase 2 clinical trial demonstrating the myelopreservation benefits of trilaciclib in patients undergoing chemotherapy treatment for 2nd/3rd-line small cell lung cancer (SCLC). Trilaciclib is a …

Satsuma Pharmaceuticals Appoints Elisabeth Sandoval to Board of Directors

Jennifer Schram Main Page, Portfolio News, Press Release, Satsuma Pharmaceuticals

Commercial leader brings recent migraine space experience to Satsuma as it advances lead product candidate STS101 into Phase 3 development SOUTH SAN FRANCISCO, Calif., May 29, 2019 /PRNewswire/ — Satsuma Pharmaceuticals, Inc. (“Satsuma” or “the Company”), a Phase 3-stage biopharmaceutical company developing STS101, …

Zymeworks Enters its First ZymeLink™ Antibody-Drug Conjugate Platform Licensing Agreement with Iconic Therapeutics

Jennifer Schram Portfolio News, Press Release, Zymeworks

VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has entered into a licensing agreement that grants Iconic Therapeutics, Inc. (Iconic) non-exclusive rights to Zymeworks’ proprietary ZymeLink™ antibody-drug conjugate (ADC) platform …

Engage Therapeutics Presents Data from Part 1, Open-label Run-in of StATES Phase 2b Study of Staccato® Alprazolam at 2019 American Academy of Neurology Annual Meeting

Jennifer Schram Engage Therapeutics, Portfolio News, Press Release

8 patients with predictable generalized or focal epileptic seizures treated with Staccato alprazolam 62.5% of patients respond with the cessation of seizure activity within two minutes of therapy administration and no recurrence of seizure activity within two hours Feasibility of …

Medexus Pharmaceuticals Launches New Dosage for Treatment of Rheumatoid Arthritis, Psoriasis & Psoriatic Arthritis in Canada

Jennifer Schram Medexus Pharmaceuticals, Portfolio News, Press Release

MONTREAL, May 7, 2019 — Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF), today announced the launch of a new Metoject® Subcutaneous 15mg dose in Canada. Metoject Subcutaneous is a pre-filled syringe of methotrexate with a pre-attached subcutaneous …

Bardy Diagnostics™ Selected as Winner of the Frost & Sullivan Award for Technology Innovation in Remote Cardiac Monitoring

Jennifer Schram BardyDx, Main Page, Portfolio News, Press Release

SEATTLE, May 7, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced it has been selected as the winner of the North American Remote Cardiac Monitoring Technology Innovation Award by Frost & …